General Updates

October 29, 2026 To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Acquisition Dear Sir / Madam, Pursuant to Regulation 30 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we would like to inform that the Board of Directors of the Company at its meeting held today, i.e., on October 29, 2026, inter alia, has approved for acquisition of 52% share capital of SI & C Resins Private Limited (“SI&C”) at a pre-money valuation of Rs. 30 Crore. The Company proposes to invest a total of Rs. 32.50 Crores by way of primary acquisition of 10,833 equity shares, equivalent to 52% of post-issue equity capital on Closing (the “Proposed Transaction”). SI&C specializes in the manufacturing and supply of high-quality polymer and silica-based products for the chemical, pharmaceutical, and biotechnology industries. Following such acquisition, the Company shall hold 52% of the equity share capital of SI&C, and SI&C will be a subsidiary company of the Company. The Company may also invest up to Rs. 30 Crores in the securities to be issued by SI&C as and when funds are required by SI&C. The disclosure pursuant to Regulation 30 of the SEBI Listing Regulations read with Part A of Schedule III of the SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026, is annexed herewith in Annexure-A. The Board Meeting commenced at 02.00 p.m. (IST) and concluded at 02.47 p.m. (IST). Please take the above information on record. Thanking you. Yours faithfully, For Laurus Labs Limited V V Ravi Kumar Executive Director and CFO DIN: 01424180 Encl: A/a Annexure-A Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 a Name of the target entity, details in brief Name of the target entity such as size, turnover etc. SI & C Resins Private Limited (“SI&C”) situated in Hyderabad, India. Details in brief SI&C specializes in the manufacturing and supply of high-quality polymer and silica-based products for the chemical, pharmaceutical, and biotechnology industries. Wide range of products for various applications are as hereunder: o Peptide and Peptidomimetic Synthesis; o Absorption and separation of the heavy metals; o Oxidation and reduction of the functional groups; o Counter – Ion exchange of small molecules and APIs Turnover Not applicable. SI&C is incorporated recently in July, 2026. SI&C will take over the business of a partnership firm, namely, M/s SI & C Resins (the “Firm”), wherein all the founder directors and shareholders of SI&C, are partners in the Firm. The Firm was registered in the year 2022 and has turnover for the financial year 2024-25 was Rs. 3.55 Crore and for 2025-26 was Rs. 4.05 Crore. b Whether the acquisition would fall within The acquisition would not fall within related party related party transaction(s) and whether the transaction. The promoter/ promoter group/ group promoter/ promoter group/ group companies of the Company have no interest in SI&C. companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” c Industry to which the entity being acquired SI&C specializes in the manufacturing and supply of belongs high-quality polymer and silica-based products for the chemical, pharmaceutical, and biotechnology industries. d Objects and impact of acquisition (including As part of the overall Peptide strategy, the Company but not limited to, disclosure of reasons for proposes to acquire a majority equity in SI&C and acquisition of target entity, if its business is this will make Laurus offerings in Peptide outside the main line of business of the manufacturing fully integrated. listed entity) The proposed investment in SI&C will bring synergy to the business of the Company, while SI&C continue to develop new markets for its products. Indigenous resins, chromatography gels development, and large-scale manufacturing will help to capture fully integrated peptide manufacturing opportunities. Further, SI&C will set up a large-scale manufacturing plant by SI&C for peptide resins as solid phase peptide synthesis (SPPS) supports and chromatography gels. The acquisition will help us to build on the existing customer base and product pipeline to scale domestic resin manufacturing solutions for pharma and peptide manufacturing. e Brief details of any governmental or The acquisition will be in accordance with the regulatory approvals required for the applicable provisions of the Companies Act, 2013. acquisition f Indicative time period for completion of the The Proposed Transaction is expected to be acquisition completed during the current financial year, subject to the completion of customary closing conditions and agreements which includes transfer of business of the Firm. g Consideration - whether cash consideration Cash consideration or share swap or any other form and details of the same h Cost of acquisition and/or the price at which The Proposed Transaction is contemplated by way of the shares are acquired primary subscription to 10,833 equity shares of the SI&C at a consideration of Rs. 32.50 Crores, equivalent to 52% of the post-issue paid-up equity capital of SI&C. i Percentage of shareholding / control The Company will hold 52% shareholding on closing acquired and / or number of shares acquired of the Proposed Transaction through primary subscription to equity share capital. Post the Proposed Transaction, the SI&C will be a subsidiary company of the Company. j Brief background about the entity acquired Brief background and line of business: in terms of products/line of business SI&C specializes in the manufacturing and supply of acquired, date of incorporation, history of high-quality polymer and silica-based products for last 3 years turnover, country in which the the chemical, pharmaceutical, and biotechnology acquired entity has presence and any other industries. Wide range of products for various significant information (in brief) applications are as hereunder: o Peptide and Peptidomimetic Synthesis; o Absorption and separation of the heavy metals; o Oxidation and reduction of the functional groups; o Counter – Ion exchange of small molecules and APIs Date of incorporation: SI&C is incorporated on July 15, 2026. SI&C will take over the business of a partnership firm, namely, M/s SI & C Resins (the “Firm”), wherein all the founder directors and shareholders of SI&C, are partners in the Firm. Turnover of last 3 years: Not applicable Country in which the entity has presence: SI&C has operation in India.